oops...last part didn't come across. Here it is

New Post Public Reply Private Reply Replies (1) Message Board
docj docj #26276
473
oops...last part didn't come across. Here it is again:

Here is my synopsis on te vaccines not approved by FDA but cleared for emergency use from small patient sampling’s from 40/60 thousand phase 3 trials, this is a hard ride awakening people.

We expect side effects from mRNA vaccines will become more prevalent over time and the weaknesses of mRNA vaccine technology will be exposed. Efficacy and side effect profiles observed in tightly controlled clinical trials often vary from real-world results, especially when trials are limited in scope and duration for accelerated EUA approval by a desperate FDA. In the case of COVID-19 mRNA vaccine trials, close examination of evidence suggests side effects observed in the clinical trials were downplayed or outright ignored. The best example of this is Bell’s Palsy.

In Pfizer’s trial 4 patients experienced “Bell’s Palsy” with 0 (zero) in the placebo group. In Moderna’s trial 3 patients experienced “Bell’s Palsy” with 1 in the placebo group. The FDA concluded that the “Bell’s Palsy” was not attributable to the vaccines because the event rates were similar to that seen in the general population. This logic is inconsistent with standard data interpretation and risk assessment because “Bell’s Palsy” occurred at a 400% higher rate in Pfizer’s trial and 300% higher rate in Moderna’s trial. Under normal circumstances this might have stopped the trials but under EUA it was ignored. But it gets worse... Bell’s Palsy by definition is temporary facial paralysis that completely resolves. Upon trial conclusion and FDA approval, 3 of the 4 cases in Pfizer’s trial were unresolved and 2 of the 3 cases in Moderna’s trial were unresolved (a combined 71.4% remained unresolved). The true and correct medical diagnosis at the time of FDA approval was facial paralysis. Only after paralysis resolves can it be diagnosed as Bell’s Palsy. It’s deceitful and negligent to label unresolved facial paralysis as Bell’s Palsy and was obviously done to downplay the risk and avoid reporting severe adverse events.

We suspect the facial paralysis could have been caused by non-neutralizing antibodies generated by the mRNA vaccines. Only a very small fraction of total antibodies generated from mRNA vaccines are neutralizing. The vast majority are non-neutralizing and pose a potential risk for harmful off-target binding, side effects, and autoimmunity. mRNA vaccines cannot predict or control antigen processing and presentation (i.e. how the Spike protein will be internalized by antigen processing cells, digested into peptides, processed and loaded onto MHC, and presented to the immune system for antibody production). This is a largely random process and peptides-antibodies can vary with each vaccine and booster and vary from person to person. With Generex’s Ii-Key-SARS-CoV-2 vaccine, we know exactly what peptides are being introduced. We know these peptides are being delivered in original pure form directly to MHC because Ii-Key bypasses the natural antigen processing system. Furthermore, using our computational vaccinology programs, we know our peptide sequences do not exist in the human body and harmful off-target antibody binding is not possible. We don’t use 1791 non neutralizing antibodies that Skew also very harmful Th2 from the very bad spike protein, we use only the best and safest parts, in addition these parts are in all variants and will not make our vaccine obsolete at all.

As far as being late to the vaccine race every single person who gets vaccinated by an MRNA vaccine that does not give longe term memory at all should take our vaccine because we will make them better and we can’t hurt you at all.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Applied Digital Corporation Announces Q1 2026 Earnings Call Details

Updated Category News Views 249

Upcoming Conference Call for Fiscal First Quarter 2026 On September 24, 2025, Applied Digital Corporation (Nasdaq: APLD) announced its scheduled conference call for Thursday, October 9, 2025. This call is set for 5:00 p.m. Eastern Time and will encompass key discussions around the company's operations and financial outcomes for the fiscal first quarter that ended on...

Continue Reading
Corero Network Security Expands into Southeast Asia with ONESECURE

Updated Category News Views 147

Corero Network Security Partners with ONESECURE Asia Today, Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a leading authority in DDoS protection, announced its strategic alliance with ONESECURE Asia Pte Ltd. This partnership symbolizes Corero's successful entrance into the Southeast Asian market, emphasizing its commitment to enhancing digital security. Expanding...

Continue Reading
Pinterest Faces Challenges Following Q4 Results and Outlook

Updated Category News Views 231

Pinterest Faces Challenges Following Q4 Results Pinterest recently encountered hurdles as its stock faced significant declines after hours due to disappointing results for the fourth quarter. While the platform showed some growth, it ultimately missed key expectations, causing investors to react cautiously. Quarterly Performance Overview The platform reported...

Continue Reading
Oil Giants Face Difficult Decisions Amidst Price Drops

Updated Category News Views 47

Understanding the Challenges Facing Major Oil Companies As global energy prices decline, major oil companies are grappling with a challenging financial landscape. Analysts predict that these firms will need to borrow substantial amounts or reduce their share repurchase rates in response to falling oil prices. Historical Context of Shareholder Payouts For years, companies...

Continue Reading
Exploring the Rise of Smart Cities in Saudi Arabia

Updated Category News Views 156

Transformation of Urban Living in Saudi Arabia As the world increasingly embraces technological advancements, the Saudi Arabia smart cities market is on a promising trajectory. The valuation of this market is expected to surge from USD 22.2 billion to an impressive USD 112 billion in the coming years, signaling robust growth driven by an impressive compound annual growth...

Continue Reading